Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Gold Trust (IAU) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

IAU stock trades at $78.88, up 2.36% with a $1.82 daily gain, though technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, with support levels at $76-$77 and resistance at $78-$79. Recent news highlights gold's sensitivity to inflation data and interest rate expectations.

The outlook remains cautious due to macroeconomic headwinds and technical weakness. Investment opportunities exist if gold prices stabilize amid inflation concerns, but risks include persistent rate hikes and dollar strength. Monitor Fed policy and economic data for directional cues.